Humana Recombinant Antibodies for Cancer Therapy: Methods and Protocols: 207 (Methods in Molecular Biology, 207)

Product Description Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients. Review "...the book is well written and the experimental protocols that were included are described in great detail...this book is a valuable resource both for persons new to this field to get an overview of current activities and for those already in the field to look up specific areas that are covered." -Clinical Immunology "Overall the book is a helpful resource, especially for molecular biologists involved in generating antibody fragments, collecting up to date protocols in one convenient volume." - Pharmaceutical Research From the Back Cover Many antibodies recently developed as therapeutic agents have been tailored by the powerful new recombinant antibody technology, and already their clinical data show highly encouraging results. In Recombinant Antibodies for Cancer Therapy: Methods and Protocols, Martin Welschof and Jürgen Krauss present a collection of carefully selected protocols for the design, construction, and characterization of those novel anticancer therapeutics. Written by seasoned investigators who have successfully verified the particular method described, these readily reproducible methods include coverage of hybridoma-derived recombinant antibodies, recombinant antibody fragments from phagemid-displayed antibody repertoires, antibody fragments with additional properties, and large-scale production of recombinant antibodies for clinical applications. The main focus is on providing detailed protocols that describe these procedures step-by-step, accompanied by a troubleshooting guide discussing possible problems and offering many tips for their potential solutions. Concise review articles also survey the current status of recombinant antibodies in cancer therapy, as well as the generation of antibody molecules through antibody engineering. Up-to-date and highly practical, Recombinant Antibodies for Cancer Therapy: Methods and Protocols surveys the current status of engineered antibodies and describes in rich detail many readily reproducible methods of generating the novel and promising antibody-based reagents of today's cancer therapy.